SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Munch-a-Biotech Today
An SI Board Since December 1998
Posts SubjectMarks Bans
3158 136 0
Emcee:  Biomaven Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1258Signature and PDLI. Press Release SOURCE: Signature BioScience Signature Acquirkeokalani'nui-1/29/2002
1257Big bite, not yet a munch. Friend or foe of BSTE takes 17% interest. sec.govaknahow-1/25/2002
1256Arbitrage Spreads On Pending Mergers & Acquisitions from djones The follIan@SI-1/23/2002
1255Sounds like DoubleTwist to me.<EOM> BJBiotech Jim-1/15/2002
1254A smidgen of color from GenomeWeb on Invitrogen's H&Q presentation, in wtuck-1/15/2002
1253HEIDELBERG, Germany, & CLEVELAND--(BUSINESS WIRE)--Jan. 15, 2002--LION bioscnigel bates-1/15/2002
1252NOVATO, Calif., Jan. 14 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq andnigel bates-1/14/2002
1251biz.yahoo.com {Chiron takes out Matrix for cash, ~ $2.30/share}tommysdad-1/8/2002
1250MCLS munched by deCode. Approximately $3/share, 0.31 shares of deCode per MCLS.scaram(o)uche-1/8/2002
1249Biotechs attractive as takeover targets: Amgen's purchase of Immunex signalsim1-12/27/2001
1248<<When biotech stocks sank to year lows at the end of March, there was a saknahow-12/26/2001
12472001 Review: Biotechs Talk Turkey By Adam Feuerstein Staff Reporter 12/26/200smh-12/26/2001
1246biz.yahoo.com Interesting wording on early redemption of coverts by Chugai. <aknahow-12/25/2001
1245<< Hmm 2 times sales...>> =UPDATE: Roche Japan Deal Good, But WeakneSpekulatius-12/20/2001
1244Good point, but Roche only bought 51%. This is still a relatively low price to John Metcalf-12/20/2001
1243I think the Price to sales ratio for Roche's Chugai buy was very low - belowSpekulatius-12/19/2001
1242Interesting line of speculation, George (getting out of yen). Another aspect isJohn Metcalf-12/19/2001
1241Takeda looking for in licensing deals. If they also decide to munch an entire caknahow-12/19/2001
1240Starting to sound more and more like a probable munchee... ++++++++ Paul J. HaIan@SI-12/19/2001
1239Growing together (some comments from Financial Times) As the science and manageIcebrg-12/19/2001
1238news.bbc.co.uk With overnight rates already at zero and the BOJ empowered to inaknahow-12/19/2001
1237Mike, You're right, Adam Feuerstein is a journalist. I had him confused witDoc Bones-12/17/2001
1236I think this merger makes a load of sense. Immunex is terrible when it comes toHarold Engstrom-12/17/2001
1235Amgen's high risk strategy: Rewards of buying Immunex could be huge, say Visim1-12/17/2001
1234He is a reporter, not a hedge fund manager. I found his comments to be interestMichael Young-12/17/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News